ClinicalTrials.gg
CompletedNCT03336268POINTUpdated Oct 6, 2023Results posted

Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention

An interventional study of POINT in Substance Use Disorders and Overdose, sponsored by Indiana University. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Indiana University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 17 studies in Substance-Related Disorders by Indiana University — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Indiana University.

Enrollment
5th of 13
249 · median 120
Started
2018
with 2 others
No phase
12 of 17
5 open now
Registered
3rd of 17
by date

Among the 17 studies in Substance-Related Disorders by Indiana University, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2018, is one of 12 with no phase, and was the 3rd registered.

Substance-Related Disorders

2,241 studies on the registry are indexed under Substance-Related Disorders; 410 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 17 studies in Substance-Related Disorders by Indiana University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 265 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Substance-Related Disorders by Indiana University, or all of them as a file.
02

Study summary

The investigators seek to assess the effectiveness of Project POINT (Planned Outreach, Intervention, Naloxone, and Treatment). As originated in Indianapolis, Project POINT is a collaboration between Indianapolis Emergency Medical Services (EMS), the Eskenazi Emergency Department, Midtown Mental Health, and researchers at Indiana University. POINT is a quality improvement initiative that connects trained outreach workers with emergency department (ED) patients who experienced a non-fatal overdose. A member of the POINT team (a recovery coach or care coordinator with specialized training) meets patients after they have experienced an opioid overdose and, following a model of patient-centered care, offers them a range of evidence-based services including a brief assessment of high-risk behaviors, Hepatitis C and HIV testing, harm reduction counseling informed by motivational interviewing, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting

The primary goal of this project is the establishment of POINT as an effective and scalable intervention for engaging patients in MAT. This study employs a Hybrid Type 1 effectiveness implementation design to take full advantage of current POINT expansion efforts currently happening in Indiana. The goal of this study is to replicate POINT in new hospitals and test its feasibility through (a) assessment of the chosen implementation strategy and (b) the testing of research protocols and secondary data collection procedures.

Read the detailed description

STUDY DESIGN The investigators will conduct the pilot study at Indiana University Health Methodist Hospital in Indianapolis, Indiana and at Indiana University Health Ball Memorial Hospital in Muncie, Indiana.

The pilot study includes two study arms.

Arm(1): Regarding the POINT intervention, a recovery coach (someone certified by the Indiana Counselors' Association on Alcohol and Drug Abuse to deliver recovery supports who has lived experience with addiction) meets patients in the ED after they have been revived from an overdose (patients are typically alert and oriented, as the overdoes reversal drug completely stops the effect of opioids in their system, and patients will not be approached until a physician has determined they are eligible for release). As part of the POINT program, the recovery coach offers the patient a range of evidence-based services including a brief assessment of high-risk behaviors, Hepatitis C and HIV testing, harm reduction counseling informed by motivational interviewing, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting-with most patients choosing MOUD referral. Patients are offered a take-home naloxone kit (the overdose reversing drug, which is offered as part care delivered by the recovery coach) and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Grounded in the concept of critical time intervention, recovery coaches provide over the phone or in person support to navigate barriers to care throughout the recovery process. Also as part of the POINT program, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver (no data collection for research purposes will occur as part of this service provision). The entire care transition process takes between 2 weeks and several months, and POINT leaves the door open so patients can re-engage at any point they require help overcoming recovery barriers.

Arm (2): The standard care arm will consist of basic referral to services by informing patients of available treatment options in the community.

RANDOMIZATION \& ENROLLMENT For each day of the study, researchers will randomly select during which of the shifts patients will enroll into the POINT arm and which will enroll into standard care (morning shift (8am-3:59pm), evening (4pm-11:59pm), and overnight (12am-7:59am). Any individual who is discharged from the ED for an opioid overdose or for an opioid-related health issue, including opioid withdrawal, abscess (from IV drug use) or active opioid intoxication will be eligible for the study. The research team and recovery coaches will receive an electronic alert from emergency medical services any time an overdose patient is admitted to the ED. A recovery coach will be sent to the ED on POINT shifts, and a research assistant will be sent on non-POINT shifts. Once they have confirmed that the admit is reason is either an opioid overdose or an opioid-related issue, they will read the questions on the DSM-5 for Opioid Use Disorder screening tool. Any individual who is at least 18 years of age and is discharged from the ED for an overdose an opioid related health issue AND scores at least a "1" on the opioid use disorder screening tool will be initially eligible for the study; they must also be cleared for discharge and medically stable and capable of providing consent. Depending on the arm of the study patients are being recruited to on that shift, either the recovery coach or the research assistant will inform the patient of the study and request their consent to participate.

Researchers will not fully disclose the purposes of the research to the standard care arm because (1) Methodist Hospital and Ball Memorial were planning on implementing POINT outside of the context of this study and because their ability to staff recovery coaches is limited anyway, we are not creating any disparity in patients ability to access point that would not naturally exist and (2) we are concerned that full disclosure of the purposes would unnecessarily upset standard care patients who might desire the services after learning of them.

The study site plans to implement Project POINT regardless of the research study. Therefore, all recovery coach duties are part of POINT prescribed services that would be carried out regardless of the research. The investigators are randomizing the shift during which POINT is delivered to take advantage of the fact that they are not able to fully staff all hospital shifts with a recovery coach--thus allowing us to test the intervention's effectiveness. Only those patients in the standard care arm will be asked to complete data collection activities that would not be completed outside of the research study.

After study consent, all subjects will be asked to complete a structured interview with either a recovery coach (POINT group) or a research assistant (standard care). This interview will occur in the ED, and it can take between 30-60 minutes and covers the following topics: demographics, social support; living arrangements, drug use, context of current overdose, treatment history, interest in recovery services, use of strategies to reduce risks related to drug use, HIV and Hepatitis C, physical and mental health, adverse childhood experiences, and detailed contact information. Additionally, the RA or recovery coach will collect detailed contact information on the participant to increase chances of being able to follow up with the participant. This contact information will be entered into a separate database and will not be linked to questionnaire responses.

The investigators will also collect information from the following existing secondary data sources:

  • Indiana Network for Patient Care (contains hospital and overdose admission data)
  • INSPECT (contains prescription information for controlled substances)
  • Division of Mental Health and Addiction (contains methadone treatment information)
  • Indiana Office of Medicaid Planning and Policy (contains Medicaid enrollment information)
  • Indiana Department of Child Services (contains child welfare involvement information)
  • Valle Vista Health System (contains addiction and mental health treatment data)
  • Midtown Community Mental Health (contains mental health treatment data)
  • Clean Slate (contains addiction treatment data)

As part of the POINT project, recovery coaches engage with POINT patients for two weeks (reaching out to patients every 2-3 days until the patient is successfully engaged in recovery services), but this may last longer (several months) depending on patient need and desire for continued assistance. Recovery coaches will not be collecting data for study purposes during this time; rather, any information they collect will be their employment purposes as a recovery coach. Standard care patients are not seen after the initial referral.

The investigators will also collect data from hospital records and government and public health databases on patients enrolled in the study after obtaining a release for these information from subjects. The investigators will collect methadone data from the Division of Mental Health and Addiction (DMHA), prescribing information related to controlled substances from INSPECT (prescription drug monitoring system), the hospital admission data from Indiana Network for Patient Care (INPC), overdose death information form coroner records, insurance information from Medicaid, child welfare system involvement form the Department of Child Services (DCS), and publicly available criminal justice data. A third party, Regenstrief Institute, will work with all of these systems to securely obtain and merge the data and to de-identify the data before sharing it with the research team.

03

Conditions studied

  • Substance Use Disorders
  • Overdose

Keywords

  • Opioid Use Disorder
  • Peer Recovery Coach
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Revived from a drug overdose or admitted to the ED for an opioid-related health issue, including opioid withdrawal, abscess (from IV opioid use), endocarditis (from IV opioid use), or active opioid intoxication
  2. Score at least "1" on the for Opioid Use Disorder screening tool
  3. Eligible for discharge from the Methodist or Ball Memorial Hospital Emergency Department and deemed able to speak to research staff by ED staff
  4. Be 18 or older
  5. Be medically stable (i.e., cleared to leave the ED by a physician) and capable of providing consent.

Exclusion criteria

Exclusion Criteria:

(a) Unable to answer the 3 study competency questions that indicate capability of providing consent.

(Individuals discharged from the ED during a POINT shift who do not wish to participate in the study are still eligible to receive POINT services.)

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    POINT

    This arm will be offered both POINT services (in addition to standard emergency care) and enrollment in study data collection. If they choose to enroll in POINT, they may choose whether or not to enroll in data collection, as it is not required. Should they enroll in data collection, they will be consented and enrolled in the research study as a participant in the POINT study arm.

    Behavioral: POINT

  • No intervention
    Standard Care

    This arm will only be offered enrollment in study data collection, as they will receive standard emergency care. If they choose to enroll, they will be consented in the research study as the Standard Care arm.

Interventions

  • BehavioralPOINT

    A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.

06

What researchers measure

Primary outcomes

  1. Opioid Overdose

    Total participants presenting to the emergency department (ED) for an opioid overdose.

    Time frame: 1 year pre-enrollment through 1 year post-enrollment

Secondary outcomes

  1. Medication for Opioid Use Disorder (MOUD) Engagement

    Total participants with buprenorphine prescriptions, naltrexone prescriptions, or dosed methadone.

    Time frame: 1 year pre-enrollment through 1 year post-enrollment

  2. Duration of Medication for Opioid Use Disorder (MOUD) Engagement

    Total days of supply of buprenorphine prescriptions, naltrexone prescriptions, or methadone dosed for participants with a medication for opioid use disorder (MOUD).

    Time frame: 1 year pre-enrollment through 1 year post-enrollment

  3. Emergency Department Presentations

    Total participants presented to the Emergency Department for any medical reason.

    Time frame: 1 year pre-enrollment through 1 year post-enrollment

  4. Inpatient Hospital Admissions

    Total participants admitted to the hospital for any medical reason.

    Time frame: 1 year pre-enrollment through 1 year post-enrollment

  5. Time to Relapse

    Relapse-free survival probability for 6 months and 12 months. Participants who did not have ED presentation were censored at 1) time of 6 month or 12 months, 2) one's last day in the study, 3) overdose death date, whichever is the earliest.

    Time frame: Enrollment through 6 & 12 months post-enrollment

  6. Medicaid Enrollment for Participants Without Insurance

    Total participants without insurance coverage at enrollment that enrolled in Medicaid.

    Time frame: Enrollment through 3 months, 6 months, and 12 months post-enrollment

  7. Child Welfare Involvement

    Total open child welfare cases.

    Time frame: 3 years pre-enrollment through 1 year post-enrollment

  8. Incarceration

    Total days experienced incarceration.

    Time frame: 3 years pre-enrollment through 1 year post-enrollment

07

Results

Posted Apr 28, 2023
Limitations and caveats
Because of IRB requirements, the control arm was enrolled by research assistants and the treatment arm was enrolled by peers. Higher treatment arm enrollment was likely due to peers' relationship building role. The COVID pandemic stopped quality improvement efforts and enrollment before the issue could be full addressed. Thus, the study was unable to address enrollment discrepancies or reach the target sample (n=712). The study was likely underpowered to detect change in the primary outcome.

Participant flow

Participant flow — Overall Study
MilestonePOINTStandard Care
Started15990
Completed15990
Not completed00

Outcome measures

PrimaryOpioid Overdose

Total participants presenting to the emergency department (ED) for an opioid overdose.

Time frame:
1 year pre-enrollment through 1 year post-enrollment
Reported as:
Count of participants · Participants
Opioid Overdose
ParticipantsPOINTStandard Care
Within 12 months pre-enrollment189
Within 6 months pre-enrollment106
Within 3 months pre-enrollment54
Within 1 month pre-enrollment03
Within 1 month post-enrollment33
Within 3 months post-enrollment116
Within 6 months post-enrollment1511
Within 12 months post-enrollment2615
SecondaryMedication for Opioid Use Disorder (MOUD) Engagement

Total participants with buprenorphine prescriptions, naltrexone prescriptions, or dosed methadone.

Time frame:
1 year pre-enrollment through 1 year post-enrollment
Reported as:
Count of participants · Participants
Medication for Opioid Use Disorder (MOUD) Engagement
ParticipantsPOINTStandard Care
Within 12 months pre-enrollment4616
Within 6 months pre-enrollment369
Within 3 months pre-enrollment247
Within 1 month pre-enrollment83
Within 1 month post-enrollment3614
Within 3 months post-enrollment4926
Within 6 months post-enrollment6528
Within 12 months post-enrollment7738
SecondaryDuration of Medication for Opioid Use Disorder (MOUD) Engagement

Total days of supply of buprenorphine prescriptions, naltrexone prescriptions, or methadone dosed for participants with a medication for opioid use disorder (MOUD).

Time frame:
1 year pre-enrollment through 1 year post-enrollment
Reported as:
Median · days
Duration of Medication for Opioid Use Disorder (MOUD) Engagement
daysPOINTStandard Care
Within 12 months pre-enrollment45.0 (16.0 to 194.0)44.6 (27.0 to 121.0)
Within 6 months pre-enrollment41.0 (14.0 to 88.1)29.0 (18.0 to 97.0)
Within 3 months pre-enrollment16.0 (10.4 to 43.4)36.9 (14.0 to 48.9)
Within 1 month pre-enrollment14.0 (9.0 to 19.0)14.0 (9.0 to 14.0)
Within 1 month post-enrollment17.7 (6.7 to 24.9)15.9 (8.0 to 30.0)
Within 3 months post-enrollment39.0 (21.0 to 64.3)30.0 (8.0 to 63.3)
Within 6 months post-enrollment47.6 (21.6 to 95.0)47.3 (36.0 to 106.5)
Within 12 months post-enrollment84.0 (30.0 to 168.0)53.5 (22.0 to 207.3)
SecondaryEmergency Department Presentations

Total participants presented to the Emergency Department for any medical reason.

Time frame:
1 year pre-enrollment through 1 year post-enrollment
Reported as:
Count of participants · Participants
Emergency Department Presentations
ParticipantsPOINTStandard Care
Within 12 months pre-enrollment9952
Within 6 months pre-enrollment7743
Within 3 months pre-enrollment5530
Within 1 month pre-enrollment2918
Within 1 month post-enrollment3418
Within 3 months post-enrollment6330
Within 6 months post-enrollment8247
Within 12 months post-enrollment10256
SecondaryInpatient Hospital Admissions

Total participants admitted to the hospital for any medical reason.

Time frame:
1 year pre-enrollment through 1 year post-enrollment
Reported as:
Count of participants · Participants
Inpatient Hospital Admissions
ParticipantsPOINTStandard Care
Within 12 months pre-enrollment4423
Within 6 months pre-enrollment2917
Within 3 months pre-enrollment219
Within 1 month pre-enrollment104
Within 1 month post-enrollment4817
Within 3 months post-enrollment5220
Within 6 months post-enrollment5827
Within 12 months post-enrollment7136
SecondaryTime to Relapse

Relapse-free survival probability for 6 months and 12 months. Participants who did not have ED presentation were censored at 1) time of 6 month or 12 months, 2) one's last day in the study, 3) overdose death date, whichever is the earliest.

Time frame:
Enrollment through 6 & 12 months post-enrollment
Reported as:
Number · probability
Time to Relapse
probabilityPOINTStandard Care
Within 6 months post-enrollment0.85 (0.79 to 0.90)0.84 (0.75 to 0.91)
Within 12 months post-enrollment0.77 (0.70 to 0.83)0.74 (0.63 to 0.82)
SecondaryMedicaid Enrollment for Participants Without Insurance

Total participants without insurance coverage at enrollment that enrolled in Medicaid.

Time frame:
Enrollment through 3 months, 6 months, and 12 months post-enrollment
Reported as:
Count of participants · Participants
Medicaid Enrollment for Participants Without Insurance
ParticipantsPOINTStandard Care
Within 3 months post-enrollment107
Within 6 months post-enrollment138
Within 12 months post-enrollment1615
SecondaryChild Welfare Involvement

Total open child welfare cases.

Time frame:
3 years pre-enrollment through 1 year post-enrollment
Reported as:
Number · open cases
Child Welfare Involvement
open casesPOINTStandard Care
36 months pre-enrollment2013
24 months pre-enrollment1912
12 months pre-enrollment108
6 months pre-enrollment54
3 months pre-enrollment21
1 month pre-enrollment00
1 month post-enrollment11
3 months post-enrollment12
6 months post-enrollment44
12 months post-enrollment94
SecondaryIncarceration

Total days experienced incarceration.

Time frame:
3 years pre-enrollment through 1 year post-enrollment
Reported as:
Median · days
Incarceration
daysPOINTStandard Care
Within 3 years pre-enrollment88.0 (17.0 to 263.0)73.5 (11.0 to 347.0)
Within 2 years pre-enrollment39.0 (11.0 to 157.0)30.5 (9.0 to 183.5)
Within 12 months pre-enrollment10.0 (3.0 to 47.0)18.0 (5.0 to 76.0)
Within 6 months pre-enrollment6.5 (3.0 to 21.5)10.5 (5.0 to 71.0)
Within 3 months pre-enrollment5.5 (2.5 to 19.5)8.5 (4.0 to 25.0)
Within 1 month pre-enrollment6.5 (3.5 to 14.5)3.0 (2.0 to 13.0)
Within 1 month post-enrollment13.0 (5.0 to 24.0)5.5 (3.0 to 8.0)
Within 3 months post-enrollment11.0 (4.0 to 44.0)9.0 (4.0 to 50.0)
Within 6 months post-enrollment15.0 (4.5 to 51.0)10.0 (3.0 to 39.0)
Within 12 months post-enrollment19.0 (5.0 to 104.0)13.0 (6.0 to 47.0)
Post-hocOpioid Prescriptions (Excluding Medications for Opioid Use Disorder (MOUD) Prescriptions)

Total participants with opioid prescriptions, excluding Medications for Opioid Use Disorder (MOUD) prescriptions.

Time frame:
1 year pre-enrollment through 1 year post-enrollment
Reported as:
Count of participants · Participants
Opioid Prescriptions (Excluding Medications for Opioid Use Disorder (MOUD) Prescriptions)
ParticipantsPOINTStandard Care
Within 12 months pre-enrollment4430
Within 6 months pre-enrollment3120
Within 3 months pre-enrollment1815
Within 1 month pre-enrollment1815
Within 1 month post-enrollment1815
Within 3 months post-enrollment86
Within 6 months post-enrollment147
Within 12 months post-enrollment199
Post-hocBenzodiazepine Prescriptions

Total participants with benzodiazepine prescriptions.

Time frame:
1 year pre-enrollment through 1 year post-enrollment
Reported as:
Count of participants · Participants
Benzodiazepine Prescriptions
ParticipantsPOINTStandard Care
Within 12 months pre-enrollment1711
Within 6 months pre-enrollment168
Within 3 months pre-enrollment136
Within 1 month pre-enrollment65
Within 1 month post-enrollment105
Within 3 months post-enrollment156
Within 6 months post-enrollment177
Within 12 months post-enrollment2111
Post-hocNarcan Prescriptions

Total participants with Narcan prescriptions.

Time frame:
1 year pre-enrollment through 1 year post-enrollment
Reported as:
Count of participants · Participants
Narcan Prescriptions
ParticipantsPOINTStandard Care
Within 12 months pre-enrollment104
Within 6 months pre-enrollment73
Within 3 months pre-enrollment53
Within 1 month pre-enrollment30
Within 1 month post-enrollment73
Within 3 months post-enrollment113
Within 6 months post-enrollment136
Within 12 months post-enrollment179
Post-hocMedicaid Enrollment for Participants With Insurance

Total participants with insurance coverage at enrollment that enrolled in Medicaid.

Time frame:
Enrollment through 3 months, 6 months, and 12 months post-enrollment.
Reported as:
Count of participants · Participants
Medicaid Enrollment for Participants With Insurance
ParticipantsPOINTStandard Care
Within 3 months post-enrollment7838
Within 6 months post-enrollment8341
Within 12 months post-enrollment8647

Adverse events

Collected over One year pre-enrollment through one year post-enrollment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
POINT25/157 (15.9%)102/157 (65%)0/157 (0%)
Standard Care16/86 (18.6%)56/86 (65.1%)0/86 (0%)
Most frequent serious events
Most frequent serious events
EventPOINTStandard Care
Emergency Department PresentationGeneral disorders102/15756/86
Inpatient Hospital AdmissionGeneral disorders71/15736/86
Opioid OverdoseInjury, poisoning and procedural complications29/15719/86
Most frequent other events
Most frequent other events
EventPOINTStandard Care
Violation of ConfidentialitySocial circumstances0/1570/86
Discomfort Due to InterviewSocial circumstances0/1570/86
Disclosure of Information About Harm to Self/OthersSocial circumstances0/1570/86

Baseline characteristics

Of the 249 participants enrolled in the study, only 243 were included in the analysis (POINT arm=157; Standard Care arm=86). A total of 6 participants, including 2 participants from the POINT arm and 4 participants from the Standard Care arm, were excluded from the analysis because they were unable to be matched to administrative records.

Age, Continuous
Age, Continuous(years)POINTStandard CareTotal
Mean35 ± 10.137.2 ± 11.735.8 ± 10.7
Sex/Gender, Customized
Sex/Gender, Customized(Participants)POINTStandard CareTotal
Female6832100
Male8854142
Other101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)POINTStandard CareTotal
Hispanic or Latino325
Not Hispanic or Latino15384237
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)POINTStandard CareTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American171128
White13975214
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)POINTStandard CareTotal
United States15786243
Insurance Status
Insurance Status(Participants)POINTStandard CareTotal
Healthy Indiana Plan (HIP)9145136
Medicaid17825
Medicare7613
Private (exchange, employer-based)10313
Other145
None302050
Unknown101
08

Study locations

2 sites
  • Indiana University Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
  • Indiana University Health Ball Memorial Hospital
    Muncie, Indiana 47303, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Dec 2021, 45 months.

Results were first posted in Apr 2023, 1 year 4 months after primary completion.

Of 814 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's 45 months is above that.

Counting every sponsor, half of 854 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Nov 8, 2017
StartActual
Feb 12, 2018
Primary completionActual
Dec 9, 2021
CompletionActual
Dec 9, 2021
Results first posted
Apr 28, 2023
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03336268
Lead sponsor
Indiana University
Responsible party
Alan McGuire (Principal Investigator, Indiana University) — Principal investigator
First posted
Nov 8, 2017
Start date
Feb 12, 2018
Primary completion
Dec 9, 2021
Completion
Dec 9, 2021
Results posted
Apr 28, 2023
Last update
Oct 6, 2023

Study contacts

Dennis P Watson, PhD
principal investigator · Indiana University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion